Síndrome de Guillain-Barré

Referencias

1. 1.  Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des réflexes tendineux. Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris 1916;40:1462-70.
2. Hughes RAC, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130:2245-57.
3. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and aref lexia). N Engl J Med 1956;255:57-65.
4. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-6.
5. Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012;83: 23-8.
6. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff’s brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008;255:674-82.
7. Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82:294-9.
8. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33.
9. Poropatich KO, Walker CL, Black RE. Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review. J Health Popul Nutr 2010;28:545-52.
10. Hadden RDM, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001;56:758-65.
11. Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998;51:1110-5.
12. Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 2011;52:837-44.
13. Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 2010;51:525-30.
14. Lehmann HC, Hartung HP, Kieseier BC, Hughes RAC. Guillain-Barré syndrome after exposure to inf luenza virus. Lancet Infect Dis 2010;10:643-51.
15. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain-Barré syndrome and adjuvanted pandemic inf luenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011;343:d3908.
16. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599-612.
17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:Suppl:S21-S24.
18. Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal f luid examination. J Neuroimmunol 2004;148:200-5.
19. Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2009;80:56-9.
20. Yuki N, Kokubun N, Kuwabara S, et al. Guillain-Barré syndrome associated with normal or exaggerated tendon ref lexes. J Neurol 2011 December 6 (Epub ahead of print).
21. Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from f luctuating Guillain-Barré syndrome: a prospective study. Neurology 2010;74:1680-6.
22. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology 2003;61:471-4.
23. Hughes RAC, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62:1194-8.
24. van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589-94.
25. Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011; 76:968-75.
26. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010;67:781-7.
27. Asbury AK, Arnason BG, Adams RD. The inf lammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine (Baltimore) 1969;48:173-215.
28. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute f laccid paralysis in China. Ann Neurol 1993;33:333-42.
29. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998;44:780-8.
30. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
31. Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barré syndrome associated with Campylobacter infection in Bangladesh. Neurology 2010;74: 581-7.
32. Nachamkin I, Arzarte Barbosa P, Ung H, et al. Patterns of Guillain-Barré syndrome in children: results from a Mexican population. Neurology 2007;69:1665-71.
33. Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157-63.
34. Capasso M, Notturno F, Mazoli C, Uncini A. Involvement of sensory fibers in axonal subtypes of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2011;82:664-70.
35. Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A. Acute motor conduction block neuropathy: another Guillain-Barré syndrome variant. Neurology 2003;61:617-22.
36. Ropper AH. Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994;51:671-5.
37. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007;64:1519-23.
38. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986;43:1150-2.
39. Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63:494-500.
40. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64:1605-11.
41. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inf lammatory demyelinating polyneuropathy. Ann Neurol 1996; 39:625-35.
42. Hafer-Macko C, Hsieh S-T, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44.
43. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor
44. axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996; 25:33-51.
45. Dehaene I, Martin JJ, Geens K, Cras P. Guillain-Barré syndrome with ophthalmoplegia: clinicopathologic study of the central and peripheral nervous systems, including the oculomotor nerves. Neurology 1986;36:851-4.
46. Lopez PH, Zhang G, Zhang J, et al. Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair. J Neurosci 2010;30:9533-41.
47. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum antiGQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-7.
48. Liu JX, Willison HJ, Pedrosa-Domellof F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009; 50:3226-32.
49. Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002;72:767-71.
50. Kusunoki S, Kaida K. Antibodies against ganglioside complexes in Guillain-Barré syndrome and related disorders. J Neurochem 2011;116:828-32.
51. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993; 178:1771-5.
52. Houliston RS, Koga M, Li J, et al. A Haemophilus inf luenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry 2007;46:8164-71.
53. Willison HJ. Biomarkers in experimental models of antibody-mediated neuropathies. J Peripher Nerv Syst 2011;16: Suppl 1:60-2.
54. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67.
55. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 2004; 101:11404-9.
56. Greenshields KN, Halstead SK, Zitman FM, et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J Clin Invest 2009;119:595-610.
57. Goodfellow JA, Bowes T, Sheikh K, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to antiGD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005;25:1620-8.
58. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131:1197-208.
59. Zhang G, Lehmann HC, Bogdanova N, Gao T, Zhang J, Sheikh KA. Erythropoietin enhances nerve repair in antiganglioside antibody-mediated models of immune neuropathy. PLoS One 2011; 6(10):e27067.
60. Zhang G, Lehmann HC, Manoharan S, et al. Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth. J Neurosci 2011;31:1664-75.
61. Pineda AA, Minohara M, Kawamura N, et al. Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis. J Neurol Sci 2011;306:115-20.
62. Drenthen J, Yuki N, Meulstee J, et al. Guillain-Barré syndrome subtypes related to Campylobacter infection. J Neurol Neurosurg Psychiatry 2011;82:300-5.
63. Kuwabara S, Ogawara K, Misawa S, et al. Does Campylobacter jejuni infection elicit “demyelinating” Guillain-Barré syndrome? Neurology 2004;63:529-33.
64. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.
65. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30.
66. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-6.
67. Burakgazi AZ, Höke A. Respiratory muscle weakness in peripheral neuropathies. J Peripher Nerv Syst 2010;15:307-13.
68. Bos Eyssen ME, van Doorn PA, Jacobs BC, et al. Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndrome. Neurocrit Care 2011;15:128-33.
69. Khan F, Ng L, Amatya B, Brand C, Turner-Stokes L. Multidisciplinary care for Guillain-Barré syndrome. Eur J Phys Rehabil Med 2011;47:607-12.
70. Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology 2010;75: 1439-47.
71. Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA. Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. J Neurol 2007;254: 1318-22.
72. Garssen MP, van Koningsveld R, van Doorn PA. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome. J Neurol 2006;253:1143-6.
73. Graham RC, Hughes RAC, White CM. A prospective study of physiotherapist prescribed community based exercise in inf lammatory peripheral neuropathy. J Neurol 2007;254:228-35.
74. Cochen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome. Brain 2005;128:2535-45.
75. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35: 1096-104.
76. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298-306.
77. van der Meché FGA, Schmitz PIM, Dutch Guillain–Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. N Engl J Med 1992;326:1123-9.
78. Jacobs BC, O’Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003;126:2220-34.
79. Zhang G, Lopez PH, Li CY, et al. Antiganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004;127: 1085-100.
80. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009;66:597-603.
81. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997;350:1747.
82. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-90.
83. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2:750-3.
84. van Koningsveld R, Schmitz PIM, van der Meché FGA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-6.
85. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144-6.
86. Susuki K, Koga M, Hirata K, Isogai E, Yuki N. A Guillain–Barré syndrome variant with prominent facial diplegia. J Neurol 2009;256:1899-905